The tablet formulation is designed for oral absorption, but correct timing is important because food and other medicines can reduce how much semaglutide the body absorbs
If you have previously experienced injection site reactions to other subcutaneous medications, this should be mentioned
To date, the only dose-specified, comparator, inclusive study between patients with obesity with and without a history of MBS, was conducted in 2024 26
For more information, please refer to the section below
Anticipating Volume Loss in High-Risk Patients Preventive intervention is key when prescribing semaglutide to patients with low baseline facial fat or high aesthetic concern
Clinical Evidence Aspiration Risk Evidence The clinical evidence regarding GLP-1 RA-associated aspiration risk has evolved from alarming case reports to more nuanced observational data